{"id":"NCT03859427","sponsor":"Amgen","briefTitle":"A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","officialTitle":"A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-08","primaryCompletion":"2023-03-31","completion":"2023-03-31","firstPosted":"2019-03-01","resultsPosted":"2024-04-18","lastUpdate":"2024-08-13"},"enrollment":454,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Carfilzomib","otherNames":[]},{"type":"DRUG","name":"Carfilzomib","otherNames":[]},{"type":"DRUG","name":"Lenalidomide","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Carfilzomib once-weekly","type":"ACTIVE_COMPARATOR"},{"label":"Carfilzomib twice-weekly","type":"ACTIVE_COMPARATOR"}],"summary":"Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.","primaryOutcome":{"measure":"Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)","timeFrame":"Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.","effectByArm":[{"arm":"Twice-weekly KRd 20/27 mg/m^2","deltaMin":86.3,"sd":null},{"arm":"Once-weekly KRd 20/56 mg/m^2","deltaMin":82.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0666"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":108,"countries":["United States","Austria","Bulgaria","Czechia","Finland","France","Germany","Greece","Japan","Lithuania","Netherlands","Romania","Russia","Slovakia","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["39024542"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":231},"commonTop":["Neutropenia","Anaemia","Hypertension","Diarrhoea","Thrombocytopenia"]}}